Herpes zoster complicating bortezomib therapy of relapsed/refractory indolent B-cell and mantle cell lymphoma: an analysis of two phase II trials

    Authors

    M. Solh; R. I. Fisher; A. Goy; S. de Vos; S. H. Bernstein; D. L. Esseltine; R. Neuwirth;V. A. Morrison

    Comments

    Authors: contact us about adding a copy of your work at [email protected]

    Abbreviated Journal Title

    Leuk. Lymphoma

    Keywords

    Herpes zoster; bortezomib; non-Hodgkin lymphoma; mantle cell lymphoma; MULTIPLE-MYELOMA; PLUS MELPHALAN; DEXAMETHASONE; PREDNISONE; ACYCLOVIR; Oncology; Hematology

    Abstract

    The incidence of herpes zoster (HZ) in patients with non-Hodgkin lymphoma (NHL) receiving bortezomib-based therapy has not been well studied. We reviewed data from two phase II trials in which bortezomib was administered to 236 patients, median age 65 years, with relapsed/refractory mantle cell or indolent NHL. HZ occurred in 24 patients (10.2%) overall, with a comparable incidence in NHL histologic subgroups. Median time to HZ was 39 (range, 11-206) days. In total, 71% of patients who developed HZ were aged > = 65 years, compared to 48% without HZ (p = 0.03). Patients with HZ were more likely to have had received > = 2 lines of therapy (63% vs. 47%, p = 0.16). Six (25%) of the patients who developed HZ had received purine analogs, compared with 34 (16%) patients without HZ (p = 0.27). As the occurrence of HZ may complicate the course of indolent or mantle cell NHL in patients receiving bortezomib-based therapies, these patients, especially the elderly, should be strongly considered for antiviral prophylaxis.

    Journal Title

    Leukemia & Lymphoma

    Volume

    54

    Issue/Number

    10

    Publication Date

    1-1-2013

    Document Type

    Article

    Language

    English

    First Page

    2185

    Last Page

    2189

    WOS Identifier

    WOS:000324589800019

    ISSN

    1042-8194

    Share

    COinS
     

    Accessibility Statement

    This item was created or digitized prior to April 24, 2027, or is a reproduction of legacy media created before that date. It is preserved in its original, unmodified state specifically for research, reference, or historical recordkeeping. In accordance with the ADA Title II Final Rule, the University Libraries provides accessible versions of archival materials upon request. To request an accommodation for this item, please submit an accessibility request form.